Where 10x Genomics Stands With Analysts
Portfolio Pulse from Benzinga Insights
11 analysts have recently rated 10x Genomics (NASDAQ:TXG), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has dropped by 24.37% to $28.36. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Despite positive revenue growth, the company faces challenges with low ROE and ROA.
October 10, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics has received mixed analyst ratings, with a notable drop in the average price target. Despite positive revenue growth, the company faces challenges with low ROE and ROA.
The mixed analyst ratings and significant drop in the average price target suggest uncertainty about the company's short-term performance. While revenue growth is a positive indicator, the low ROE and ROA highlight operational challenges. These factors contribute to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100